Reversal Strategies for Dabigatran | Scott Kaatz, DO, MSc, FACP, SFHM
Reversal Strategies for Xa Inhibition | Truman J. Milling Jr, MD, FACEP
Clinical Cases in Bleeding Management | Jerrold Levy, MD, FAHA, FCCM
John Eikelboom, MD, MBBS
Alex Spyropoulos, MD
William Dager, Pharm.D, BCPS, FCSHP, FCCP, FCCM

Get Adobe Flash player Install latest flash player if you can't see this gallery.

Role of Antiplatelet and Anticoagulant Therapy in PAD and CAD
The COMPASS investigation team has published its findings from the study examining whether the efficacy and safety of rivaroxaban alone or in combination with aspirin is more effective than aspirin alone for preventing secondary cardiovascular events. In this presentation, COMPASS author Dr. D.L. Bhatt discusses the effects of rivaroxaban (2.5 mg b.i.d.) plus aspirin (100 mg q.d.), rivaroxaban (5 mg b.i.d.) or aspirin (100 mg q.d.) to affect the composite of cardiovascular death, stroke, or myocardial infarction.